District Of Columbia is currently home to 850 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
The Myelin Disorders Biorepository Project
NCT03047369
Recruiting
The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago. Researchers working in the biorepository hope to use these materials to uncover new genetic etiologies for various leukodystrophies,... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/15/2024
Locations: Children's National Medical Center, Washington, District of Columbia
Conditions: Leukodystrophy, White Matter Disease, Leukoencephalopathies, Aicardi Goutieres Syndrome, Metachromatic Leukodystrophy, TUBB4A-Related Leukodystrophy, 4H Syndrome, Krabbe Disease, Alexander Disease, Pelizaeus-Merzbacher Disease, Adrenoleukodystrophy, Adrenomyeloneuropathy, Multiple Sulfatase Deficiency, Megalencephalic Leukoencephalopathy With Subcortical Cysts, Vanishing White Matter Disease, Cockayne Syndrome, Labrune Syndrome, ADLD, Gangliosidoses, Peroxisomal Biogenesis Disorder, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, AGS, Alexanders Leukodystrophy, AxD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, GALC Deficiency, Globoid Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, MLD, PMD, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus Merzbacher Like Disease, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, GM2 Gangliosidosis, BPAN, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Register for Updates
A Study of GEn-1124 in Subjects with Acute Respiratory Distress Syndrome (ARDS)
NCT05795465
Recruiting
GEn1E-1124-002 is a two-part Phase 2 study to evaluate the safety and tolerability of GEn-1124 in subjects with ARDS. Treatment with IV infusion dosing as early as possible after ARDS diagnosis. Subjects will be given a second dose approximately 8 hours after the first dose and will continue with twice daily dosing (BID regimen) for 5 days.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/14/2024
Locations: Medstar Washington Hospital Center, Washington, D.C., District of Columbia
Conditions: Respiratory Distress Syndrome, Acute
Register for Updates
Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients with Sickle Cell Disease
NCT05861453
Recruiting
To assess the pharmacokinetics, pharmacodynamics and safety of Epeleuton capsules in adult SCD patients who are aged ≥18 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Medstar Health, Washington, District of Columbia
Conditions: Sickle Cell Disease
Register for Updates
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183
Recruiting
Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
Gender:
ALL
Ages:
All
Trial Updated:
11/13/2024
Locations: Clinical Trial Site, Washington, District of Columbia
Conditions: Atypical Hemolytic-Uremic Syndrome
Register for Updates
StrataMGT in the Reduction of Vulvar Lichen Sclerosus (LS) Symptoms
NCT06662942
Recruiting
This study is designed to evaluate the efficacy and safety of StrataMGT for the management of vulvar lichen sclerosus symptoms.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/07/2024
Locations: Centers for Vulvovaginal Disorders, DC, Washington, District of Columbia
Conditions: Vulvar Lichen Sclerosus
Register for Updates
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
NCT05849662
Recruiting
This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML patients will receive trametinib, azacitidine, fludarabine, and cytarabine.
Gender:
ALL
Ages:
Between 1 month and 21 years
Trial Updated:
11/07/2024
Locations: Children's National Medical Center, Washington, District of Columbia
Conditions: Leukemia, Juvenile Myelomonocytic, JMML, JCML, Neurofibromatosis 1, CBL Syndrome
Register for Updates
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171
Recruiting
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
Register for Updates
Nutritional Intervention for Endometriosis
NCT05175248
Recruiting
In a 12-week parallel study, women with a verified diagnosis of endometriosis will be randomly assigned to follow a low-fat plant-based diet or to stay on their usual diets for 12 weeks. Participants in both groups will be asked to make no changes to their exercise patterns for the study period. Changes in pain, quality of life, and inflammatory biomarkers from baseline to final will be the primary outcomes. Secondary outcomes will include changes in body weight, blood lipids, gut microbiome com... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
11/04/2024
Locations: Physicians Committee for Responsible Medicine, Washington, DC, District of Columbia
Conditions: Endometriosis
Register for Updates
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) Vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
NCT04139902
Recruiting
The purpose of this study is to test the effects of anti-PI-1 inhibitor (TSR-042) or anti-PD-1/anti-TIM-3 combination (TSR-042 / TSR-022) in patients with operable melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: Georgetown University Medical Center, Washington, District of Columbia
Conditions: Melanoma Stage III, Melanoma Stage IV
Register for Updates
Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P)
NCT06671132
Recruiting
The overarching goal of this study phase, Phase II component is to perform a randomized clinical trial of the refined Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain \[CBOT-Pain (or CBOT-P)\] from Phase I, compared to sham Computerized Chemosensory-Based Orbitofrontal Networks Training (CBOT) in Chronic Low Back Pain (CLBP) to determine its short- and long-term effectiveness on Pain, Negative Affect (NA), Cognition and Cortical Brain Structure (PACS), long-t... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/30/2024
Locations: Howard University, Washington, District of Columbia
Conditions: Chronic Pain, Low Back Pain
Register for Updates
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
NCT04696731
Recruiting
This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647 to define a Phase 2 dose.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/30/2024
Locations: Georgetown University Hospital, Washington, District of Columbia
Conditions: Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Register for Updates
MRI to Predict Rejection and Failure in Transplant and Cardiomyopathy Patients
NCT03822442
Recruiting
Overall Research Strategy of this protocol is to refine and validate noninvasive CMR imaging sequences with invasive hemodynamic and pathology results to create a comprehensive, noninvasive, radiation-reduced regimen for pediatric cardiomyopathy and cardiac transplant assessment. We were the first to perform MR-guided cardiac catheterization in US children, and have accumulated the largest US experience, having performed over 75 procedures to date. Our unique experience puts us in strong positio... Read More
Gender:
ALL
Ages:
6 months and above
Trial Updated:
10/30/2024
Locations: Children's National Health System, Washington, District of Columbia
Conditions: Heart Failure, Cardiac Imaging Techniques, Congenital Heart Defects
Register for Updates